THE US FDA is currently seeking
an injunction against Regenerative
Sciences for violations of current
good manufacturing practice
which have caused the adulteration
of its cultured cell products.
Having not been approved by
the FDA in the first instance, the
cell product is derived from a
patients own bone marrow or joint
fluid, to be grown processed and
mixed with drug products outside
the body before being re-injected
to the patients body.
The FDA has also said that the
product is misbranded as it lacks
adequate directions for use and
fails to bear the “Rx only” symbol.
The injunction would see the
product prevent the company from
adulterating and misbranding their
cultured cell products.
For info see www.fda.gov.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Aug 10
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.